EUCTR2004-004095-37-BE进行中（未招募）1 期
An exploratory, multi-center, randomized, open-label, single dose, crossover study to assess the safety and tolerability of 200µg of QAB149, delivered via a MDDPI, with or without the co-administration of water, with inhalation of 50µg of salmeterol, via a MDDPI, as an active comparator, in adult and adolescent patients with stable persistent asthma, or patients with COPD. - Not applicable
ovartis Pharma Services0 个研究点目标入组 100 人开始时间: 2005年8月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Male and female adult and adolescent patients who, when on a dose of QAB149, have experienced cough in either studies A2208, A2210, A2216, A2218, B2201 or B2205, and who have signed an Informed Consent Form prior to initiation of any study-related procedure, including any adjustments to asthma/COPD medication prior to Visit 1.
- •2) In the case of patients below the legal age of consent, the Informed Consent Form should also be signed by the patient’s parent / guardian.
- •3) COPD patients must have an FEV1 > 1 liter at Visit 1.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients not having experienced cough in previous QAB149 studies
研究者
相似试验
进行中（未招募）
1 期
An exploratory, multi-center, randomized, open-label, single dose, crossover study to assess the safety and tolerability of 200µg of QAB149, delivered via a MDDPI, with or without the co-administration of water, with inhalation of 50µg of salmeterol, via a MDDPI, as an active comparator, in adult and adolescent patients with stable persistent asthma, or patients with COPD. - Not applicable1) Stable persistent asthma2) COPDEUCTR2004-004095-37-SKovartis Pharma Services
进行中（未招募）
不适用
An exploratory, multi-center, randomized, open-label, single dose, crossover study to assess the safety and tolerability of 200µg of QAB149, delivered via a MDDPI, with or without the co-administration of water, with inhalation of 50µg of salmeterol, via a MDDPI, as an active comparator, in adult and adolescent patients with stable persistent asthma, or patients with COPD. - Not applicable1) Stable persistent asthma2) COPDEUCTR2004-004095-37-DEovartis Pharma Services100
招募中
2 期
An exploratory, multicenter, randomized, open-label with blind evaluation, active controlled study to evaluate the safety and efficacy of Keramod (imiquimod 50 mg/g, Gel) compared with Aldara (imiquimod 50 mg/g, Cream) for the treatment of actinic keratosis in adults.Actinic keratosis2024-515667-60-00Laboratorios Ojer Pharma S.L.68
已完成
不适用
To evaluate the safety and efficacy of herbal / nutraceutical tablet plus standard of care when compared with only standard of care in patients with benign prostatic hyperplasia.CTRI/2022/05/042513Arogyaseva Medical Academy of India AMAI151
尚未招募
不适用
Aggressive versus conservative endoscopic therapy for gastric varicesCTRI/2022/02/040188Surat Institute of Digestive Sciences